MDXG

MiMedx Group, Inc. (MDXG) | Rumor.io

MiMedx Group

MDXG

Attention (50-day avg)0%

Attention rank (50-day avg)#3,110

Bullish sentiment (50-day avg)78%

Price to earnings ratio116.8

Market capitalization683M

Earnings per share0.04

Dividend yield (TTM)—

Revenue (annual)418.6M

Net income (annual)48.6M

Social

What share of all stock conversation is about MDXG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Jul 29

MiMedx Group, Inc. ($MDXG) has entered into a definitive agreement to acquire Sanara MedTech Inc. ($SMTI) for $35 per share, with a total enterprise value of approximately $350 million.
The acquisition is expected to double surgical revenue and accelerate growth and profitability for MiMedx, which is transitioning from a primarily wound care company to a surgical company.
MiMedx's Q2 2026 earnings results reflect a decline in wound care revenue, but the company expects net sales to be in a range of $260 million to $290 million and for Adjusted EBITDA to approach breakeven on a full-year basis.

Generated by AI

Sentiment

Of the messages about MDXG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	41.18% -58.82	65.59% +1.34
Bearish	—	—	58.82% +58.82	34.41% -1.34

Bullish· Oct 30

The company has a strong financial position, with a clean balance sheet and strong free cash flow, and is profitable with millions in the bank.
The market opportunity for the company's products is enormous, with a potential market size of over $500 million, and the company is well-positioned to address this opportunity.
The company's sales and revenue are growing rapidly, with a 35% increase in Q3 sales and a 40% increase in wound care sales, and the company has raised its 2025 net sales guidance to mid-to-high teens.

Bearish· Apr 28

The company's management has been unable to deliver on its promises, with the stock price down 56% despite a 6% revenue growth.
The company's executives have been selling shares, including a recent sale of 1 million shares by prescience, which has contributed to the stock price decline.
The company's stock price is in a downtrend, with a moving average convergence divergence (MACD) histogram that has turned negative, indicating a bearish trend.

Generated by AI

Topics

Of the messages about MDXG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	42.86%
Technical Analysis	—	—	100%	15.87%
Analysts	—	—	0%	10.58%
Controversies	—	—	0%	2.12%
Earnings	—	—	0%	2.65%
Macro	—	—	0%	25.93%

Earnings· May 10

MiMedx Group, Inc. ($MDXG) may be reducing its revenue from the last quarter.
The company's guidance may be seen as misleading by the SEC.
MiMedx expects its first-quarter revenue to be higher than the same period last year.

Announcements· Jun 20

MiMedx Group, Inc. (MDXG) is not the focus of this post, which discusses Mainz Biomed's (MYNZ) advancements in colorectal cancer diagnostics at ASCO 2024.

Controversies· Nov 26

MiMedx Group, Inc. (MDXG) former CEO and COO were indicted on charges of securities fraud and conspiracy related to accounting fraud that overstated revenues from 2015-2016.
The company settled with the SEC for $1.5 million, with the SEC complaint alleging that MiMedx lied to auditors, investors, and the SEC about its financials.
The settlement and indictment may lead to additional lawsuits, including shareholder suits, VA charges for price gouging, and potential default on a loan due to the accumulating costs of legal fees and settlements.

Generated by AI

Community

Of the messages about MDXG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	61.68%
Newcomers	—	0%	0%	38.32%

Regulars· May 4

A regular participant suggests looking at Ebix, a profitable company with 40+ quarters of consistent earnings and paying dividends, which has been a victim of short attacks despite being proven innocent.
MiMedx Group, Inc. is expected to earn $0.01 per share in Q2 2023, with some participants speculating on the market's reaction to this news.
Insider William Lawrence Phelan has sold 5,200 shares of MDXG, and another participant notes that the RSI indicator has left the overbought zone, potentially affecting the market.

Newcomers· Sep 13

$MDXG is a reminder that shorting is HARD, and timing plays a big role, as seen in the recent short at $7 and cover at $6.04.
Newcomers to $MDXG are focusing on the asset's potential for a reversal, citing every minute-hourly chart as oversold and expecting a bounce towards $8.
The company's late-stage musculoskeletal clinical trials using proprietary amniotic tissue technology have top-line results that fell short of primary endpoints, leading to a significant decline in share price.

Generated by AI

News

MiMedx Says it Received Favorable Court Ruling in Axiofill Classification Matter

MiMedx (MDXG) said late Wednesday that the US District Court for the Northern District of Georgia va

6d agoYahoo Finance

Court vacates FDA rulings on MiMedx’s AXIOFILL classification

6d agoInvesting.com

Cantor Fitzgerald reiterates Overweight on MiMedx stock at $8

14d agoInvesting.com

MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Cantor Global Healthcare Conference | New York, NYWednesday, September 9, 20261:1 sessions Lake Street BIG10 Best Ideas Growth Conference | New York, NYThursday, September 10, 20261:1 sessions Investors interested in meeting with senior management at these events may contact th

21d agoYahoo Finance

Sanara MedTech Seeks Shareholder Approval for Merger With MiMedx

Tipranks Press Release.

24d agotheglobeandmail.com

Cantor Fitzgerald reiterates Overweight on MiMedx stock at $8

1mo agoInvesting.com

Also Discussed

Investors talking about MDXG also mention

#	Name	Attention
1	EBIX - Ebix, Inc.	——
2	Essent Group Ltd.ESNT	0%0
3	Credit Acceptance CorpCACC	0%0
4	ServisFirst Bancshares, Inc.SFBS	0%0
5	Organogenesis Holdings Inc. Class A Common StockORGO	0%new
6	Overstock.com IncOSTK	0%0
7	BancFirst CorpBANF	0%new
8	BYON - Beyond, Inc.	——
9	SNPO - Snap One Holdings Corp.	——
10	AerSale CorporationASLE	0%0

MiMedx Group, Inc.

Healthcare
Biotechnology

MiMedx Group, Inc. is a healthcare company focused on regenerative biologics and advanced wound care products. MiMedx Group, Inc. develops, manufactures, and markets placental tissue allografts and other biomaterial products used in wound care, surgical, burn, orthopedic, spine, sports medicine, ophthalmic, and dental applications. Its portfolio includes products derived from human placental and umbilical cord tissues, designed to support tissue repair and biologic healing in clinical settings. The company serves hospitals, physicians, and other healthcare providers through a range of wound management and surgical solutions. MiMedx Group, Inc. operates as a specialized player in the broader regenerative medicine market, with products that are used across multiple therapeutic areas where biologic tissue processing and advanced treatment options are important.

Website

Location

1775 West Oak Commons Court, NE

Marietta, GA, 30062

United States

Social

What share of all stock conversation is about MDXG?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Jul 29

MiMedx Group, Inc. ($MDXG) has entered into a definitive agreement to acquire Sanara MedTech Inc. ($SMTI) for $35 per share, with a total enterprise value of approximately $350 million.
The acquisition is expected to double surgical revenue and accelerate growth and profitability for MiMedx, which is transitioning from a primarily wound care company to a surgical company.
MiMedx's Q2 2026 earnings results reflect a decline in wound care revenue, but the company expects net sales to be in a range of $260 million to $290 million and for Adjusted EBITDA to approach breakeven on a full-year basis.

Generated by AI

Sentiment

Of the messages about MDXG that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	41.18% -58.82	65.59% +1.34
Bearish	—	—	58.82% +58.82	34.41% -1.34

Bullish· Oct 30

The company has a strong financial position, with a clean balance sheet and strong free cash flow, and is profitable with millions in the bank.
The market opportunity for the company's products is enormous, with a potential market size of over $500 million, and the company is well-positioned to address this opportunity.
The company's sales and revenue are growing rapidly, with a 35% increase in Q3 sales and a 40% increase in wound care sales, and the company has raised its 2025 net sales guidance to mid-to-high teens.

Bearish· Apr 28

The company's management has been unable to deliver on its promises, with the stock price down 56% despite a 6% revenue growth.
The company's executives have been selling shares, including a recent sale of 1 million shares by prescience, which has contributed to the stock price decline.
The company's stock price is in a downtrend, with a moving average convergence divergence (MACD) histogram that has turned negative, indicating a bearish trend.

Generated by AI

Topics

Of the messages about MDXG that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	42.86%
Technical Analysis	—	—	100%	15.87%
Analysts	—	—	0%	10.58%
Controversies	—	—	0%	2.12%
Earnings	—	—	0%	2.65%
Macro	—	—	0%	25.93%

Earnings· May 10

MiMedx Group, Inc. ($MDXG) may be reducing its revenue from the last quarter.
The company's guidance may be seen as misleading by the SEC.
MiMedx expects its first-quarter revenue to be higher than the same period last year.

Announcements· Jun 20

MiMedx Group, Inc. (MDXG) is not the focus of this post, which discusses Mainz Biomed's (MYNZ) advancements in colorectal cancer diagnostics at ASCO 2024.

Controversies· Nov 26

MiMedx Group, Inc. (MDXG) former CEO and COO were indicted on charges of securities fraud and conspiracy related to accounting fraud that overstated revenues from 2015-2016.
The company settled with the SEC for $1.5 million, with the SEC complaint alleging that MiMedx lied to auditors, investors, and the SEC about its financials.
The settlement and indictment may lead to additional lawsuits, including shareholder suits, VA charges for price gouging, and potential default on a loan due to the accumulating costs of legal fees and settlements.

Generated by AI

Community

Of the messages about MDXG, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	61.68%
Newcomers	—	0%	0%	38.32%

Regulars· May 4

A regular participant suggests looking at Ebix, a profitable company with 40+ quarters of consistent earnings and paying dividends, which has been a victim of short attacks despite being proven innocent.
MiMedx Group, Inc. is expected to earn $0.01 per share in Q2 2023, with some participants speculating on the market's reaction to this news.
Insider William Lawrence Phelan has sold 5,200 shares of MDXG, and another participant notes that the RSI indicator has left the overbought zone, potentially affecting the market.

Newcomers· Sep 13

$MDXG is a reminder that shorting is HARD, and timing plays a big role, as seen in the recent short at $7 and cover at $6.04.
Newcomers to $MDXG are focusing on the asset's potential for a reversal, citing every minute-hourly chart as oversold and expecting a bounce towards $8.
The company's late-stage musculoskeletal clinical trials using proprietary amniotic tissue technology have top-line results that fell short of primary endpoints, leading to a significant decline in share price.

Generated by AI

MiMedx Group

Social

Jul 29

Bullish· Oct 30

Bearish· Apr 28

Earnings· May 10

Announcements· Jun 20

Controversies· Nov 26

Regulars· May 4

Newcomers· Sep 13

MiMedx Says it Received Favorable Court Ruling in Axiofill Classification Matter

Court vacates FDA rulings on MiMedx’s AXIOFILL classification

Cantor Fitzgerald reiterates Overweight on MiMedx stock at $8

MIMEDX to Participate in Upcoming Investor Conferences

Sanara MedTech Seeks Shareholder Approval for Merger With MiMedx

Cantor Fitzgerald reiterates Overweight on MiMedx stock at $8

Also Discussed

MiMedx Group, Inc.

Company Information

Location

MiMedx Says it Received Favorable Court Ruling in Axiofill Classification Matter

Court vacates FDA rulings on MiMedx’s AXIOFILL classification

Cantor Fitzgerald reiterates Overweight on MiMedx stock at $8

MIMEDX to Participate in Upcoming Investor Conferences

Sanara MedTech Seeks Shareholder Approval for Merger With MiMedx

Cantor Fitzgerald reiterates Overweight on MiMedx stock at $8

Also Discussed

Social

Jul 29

Bullish· Oct 30

Bearish· Apr 28

Earnings· May 10

Announcements· Jun 20

Controversies· Nov 26

Regulars· May 4

Newcomers· Sep 13